Trump backs psychedelics, but CDMOs hold back for now

Drugmakers do not expect third-party manufacturers to increase their psychedelic services just yet, even after President Donald Trump issued an executive order designed to expedite research and potential market entry. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the…

Source: Endpoints News